B. Abbreviations, Body mass index; DAA: Direct-acting antiviral; EASL: European Association for the Study of the Liver; HCV: Hepatitis C virus; PCR: Polymerase chain reaction; PEG: Pegylated interferon

, RNA: Ribonucleic acid; SD: Standard deviation; SMV: Simeprevir

F. Bailly, M. Beaudoin, D. Giboz, K. Hartig-lavie, M. Maynard-;-morane-cavellec et al., SOF: Sofosbuvir; SVR: Sustained virological response Acknowledgments Study investigators Delphine Bonnet, Virginie Sicart

J. Foucher, J. Hiriart, A. Mathias, and J. Vergniol,

R. Anty, E. Gelsi, R. Truchi-;-elena-luckina, N. Messaoudi, J. Moussali et al., Vandoeuvre-lès, Florent Artu, Valérie Canva, Sébastien Dharancy, Alexandre Louvet

A. Funding, M. Janssen, . Gilead, . Abbvie, and R. Bms, The biobank of the cohort is stored by Cell&Co Biorepository, France Recherche Nord&sud Sida-vih Hepatites), ANR (Agence Nationale de la Recherche)

. France, 21 Department of Hepatology and Gastroenterology, 25 Department of Hepatology and Gastroenterology, CHU Limoges, U850 INSERM, Univ. Limoges, F-87000 Limoges, France. 26 ANRS (France Recherche Nord&sud Sida-hiv Hépatites), Unit for Basic and Clinical Research on Viral Hepatitis

Z. M. Younossi, F. Kanwal, S. Saab, K. A. Brown, H. B. El-serag et al., The impact of hepatitis C burden: an evidence-based approach, Aliment Pharmacol Ther, vol.39, issue.5, pp.518-549, 2014.

P. Marcellin, F. Pequignot, E. Delarocque-astagneau, J. P. Zarski, N. Ganne et al., Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption, J Hepatol, vol.48, issue.2, pp.200-207, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00324950

S. Deuffic-burban, P. Deltenre, A. Louvet, V. Canva, S. Dharancy et al., Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France, J Hepatol, vol.49, issue.2, pp.175-83, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00291044

L. I. Backus, D. B. Boothroyd, B. R. Phillips, P. Belperio, J. Halloran et al., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C, Clin Gastroenterol Hepatol, vol.9, issue.6, pp.509-525, 2011.

A. J. Van-der-meer, B. J. Veldt, J. J. Feld, H. Wedemeyer, J. F. Dufour et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, Jama, vol.308, issue.24, pp.2584-93, 2012.

P. Nahon, V. Bourcier, R. Layese, E. Audureau, C. Cagnot et al., Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications, Gastroenterology, vol.152, issue.1, pp.142-56, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01447065

M. J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam et al., Discovery of a beta-d-2?-deoxy-2?-alpha-fluoro-2?-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus, J Med Chem, vol.53, pp.7202-7220, 2010.

P. Raboisson, H. De-kock, A. Rosenquist, M. Nilsson, L. Salvador-oden et al., Structure-activity relationship study on a novel series of cyclopentanecontaining macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350, Bioorg Med Chem Lett, vol.18, issue.17, pp.4853-4861, 2008.

F. Penin, J. Dubuisson, F. A. Rey, D. Moradpour, and J. M. Pawlotsky, Structural biology of hepatitis C virus, Hepatology, vol.39, issue.1, pp.5-19, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00313693

E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-torres, T. Hassanein et al., Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, vol.368, issue.20, pp.1878-87, 2013.
DOI : 10.1056/nejmoa1214853

E. Lawitz, M. S. Sulkowski, R. Ghalib, M. Rodriguez-torres, Z. M. Younossi et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study, Lancet, vol.384, issue.9956, pp.1756-65, 2014.

E. J. Gane, C. A. Stedman, R. H. Hyland, X. Ding, E. Svarovskaia et al., Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C, N Engl J Med, vol.368, issue.1, pp.34-44, 2013.

M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-torres, K. R. Reddy, T. Hassanein et al., Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, vol.370, issue.3, pp.211-232, 2014.
DOI : 10.1056/nejmoa1306218

K. V. Kowdley, S. C. Gordon, K. R. Reddy, L. Rossaro, D. E. Bernstein et al., Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis, N Engl J Med, vol.370, issue.20, pp.1879-88, 2014.
DOI : 10.1056/nejmoa1402355

K. V. Kowdley, E. Lawitz, F. Poordad, D. E. Cohen, D. R. Nelson et al., Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1, N Engl J Med, vol.370, issue.3, pp.222-254, 2014.

S. Zeuzem, I. M. Jacobson, T. Baykal, R. T. Marinho, F. Poordad et al., Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin, N Engl J Med, vol.370, issue.17, pp.1604-1618, 2014.

P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn et al., Simeprevir plus Sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study, Hepatology, vol.64, issue.2, pp.370-80, 2016.

E. Lawitz, G. Matusow, E. Dejesus, E. M. Yoshida, F. Felizarta et al., Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study

, Hepatology, vol.64, issue.2, pp.360-69, 2015.

P. Y. Kwo, F. Poordad, A. Asatryan, S. Wang, D. L. Wyles et al., Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis, J Hepatol, vol.67, issue.2, pp.263-71, 2017.

J. J. Feld, I. M. Jacobson, C. Hezode, T. Asselah, P. J. Ruane et al., Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, vol.373, issue.27, pp.2599-607, 2015.

M. Bourliere, S. C. Gordon, S. L. Flamm, C. L. Cooper, A. Ramji et al., Velpatasvir, and Voxilaprevir for previously treated HCV infection, N Engl J Med, vol.376, issue.22, pp.2134-2180, 2017.

. Easl, Recommendations on treatment of hepatitis C 2015, J Hepatol, vol.63, issue.1, pp.199-236, 2015.

. Aasld and . Hcv, guidance : Recommendations for testing, managing, and treating hepatitis C, 2015.

. Easl, Recommendations on treatment of hepatitis C 2018, J Hepatol, vol.69, issue.2, pp.461-511, 2018.

M. S. Sulkowski, H. E. Vargas, D. Bisceglie, A. M. Kuo, A. Reddy et al., Effectiveness of Simeprevir plus Sofosbuvir, with or without ribavirin, in realworld patients with HCV genotype 1 infection, Gastroenterology, vol.150, issue.2, pp.419-448, 2016.

M. L. Shiffman, A. M. James, A. G. Long, and P. C. Alexander, Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin, Am J Gastroenterol, vol.110, issue.8, pp.1179-85, 2015.

V. Saxena, L. Nyberg, M. Pauly, A. Dasgupta, A. Nyberg et al., Safety and efficacy of Simeprevir/Sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis, Hepatology, vol.62, issue.3, pp.715-740, 2015.

L. I. Backus, P. S. Belperio, T. A. Shahoumian, T. P. Loomis, and L. A. Mole, Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. veterans, Aliment Pharmacol Ther, vol.42, issue.5, pp.559-73, 2015.

B. A. Aqel, S. Pungpapong, M. Leise, K. T. Werner, A. E. Chervenak et al., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis, Hepatology, vol.62, issue.4, pp.1004-1016, 2015.

D. Dieterich, B. R. Bacon, and S. L. Flamm, Evaluation of sofosbuvir and simeprevirbased regimens in the trio network: academic and community of a realworld, heterogenous population, Hepatology, vol.60, issue.1, pp.220-220, 2014.

S. B. Willemse, L. C. Baak, S. D. Kuiken, V. A. Van-der-sluys, K. D. Lettinga et al., Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life, J Viral Hepat, pp.1-5, 2016.

H. R. El-khayat, Y. M. Fouad, M. Maher, H. El-amin, and H. Muhammed, Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience, Gut, vol.66, issue.11, pp.2008-2020, 2017.

Z. Marino, J. M. Pascasio-acevedo, A. Gallego, M. Diago, C. Baliellas et al., High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4, Liver Int, vol.37, issue.12, pp.1823-1855, 2017.

S. Pol, M. Bourliere, S. Lucier, C. Hezode, C. Dorival et al., Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients, J Hepatol, vol.66, issue.1, pp.39-47, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01435007

H. Fontaine, A. Lazarus, S. Pol, C. Pecriaux, F. Bagate et al., Bradyarrhythmias associated with Sofosbuvir treatment, N Engl J Med, vol.373, pp.1886-1894, 2015.

A. Laurain, L. Kramer, P. Sultanik, A. Vallet-pichard, P. Sogni et al., Mortality associated with the treatment of HCV with direct-acting antivirals, Gut, vol.67, issue.1, pp.197-205, 2018.

C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim et al., Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access Programme (ANRS CO20-CUPIC) -NCT01514890, J Hepatol, vol.59, issue.3, pp.434-475, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01708037

I. Alam, K. Brown, C. Donovan, J. Forlenza, K. Lauwers et al., Real-world effectiveness of Simeprevir-containing regimens among patients with chronic hepatitis C virus: the SONET study, Open Forum Infect Dis, vol.4, issue.1, p.258, 2017.